Jacob Townsend, MD
Interventional Cardiology · Birmingham, ALNPI 1003932955
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $42,600 of the $51,969 with a category attached, or 82.0%. Endologix LLC accounts for 85.4% of it on its own, with 38 other manufacturers making up the rest. Among interventional cardiology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 271 payments — averaging $191.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Endologix LLC$44K
- Cardiovascular Systems Inc.$2K
- W. L. Gore & Associates, Inc.$2K
- Novartis$600
- Edwards Lifesciences$317
- Pfizer$221
- plus $3K from 33 others
What the payments were for
- Consulting fees$42,60082%
- Speaking & faculty fees$1,9504%
- Travel & lodging$1,1712%
- Food & beverage$6,24812%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Endologix LLC | 73 | $44,401 |
| Cardiovascular Systems Inc. | 5 | $2,036 |
| W. L. Gore & Associates, Inc. | 10 | $1,520 |
| Novartis | 42 | $600 |
| Edwards Lifesciences | 6 | $317 |
| Pfizer | 13 | $221 |
| Abbott | 7 | $208 |
| Amgen | 13 | $200 |
| Philips North America LLC | 5 | $178 |
| E.r. Squibb & Sons, L.L.C. | 10 | $176 |
| Bard Peripheral Vascular, Inc. | 2 | $175 |
| Merck | 9 | $169 |
| Boehringer Ingelheim | 8 | $148 |
| Medtronic(2 entities) | 5 | $145 |
| Sanofi-aventis U.S. LLC | 9 | $140 |
| Terumo Medical Corporation | 2 | $133 |
| Organogenesis Inc. | 1 | $118 |
| Baxter Healthcare | 1 | $117 |
| Johnson & Johnson | 8 | $115 |
| Bayer | 6 | $112 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $97 |
| Veryan Medical Incorporated | 1 | $95 |
| Boston Scientific | 4 | $81 |
| Inari Medical, Inc. | 1 | $69 |
| AstraZeneca | 4 | $61 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $42 |
| Actelion Pharmaceuticals US, Inc. | 2 | $40 |
| Biosense Webster, Inc. | 1 | $38 |
| Alnylam Pharmaceuticals Inc. | 2 | $32 |
| Atricure, Inc. | 1 | $29 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $20 |
| AbbVie | 1 | $20 |
| Angiodynamics, Inc. | 1 | $20 |
| Bridgebio Pharma, Inc. | 1 | $18 |
| Lexicon Pharmaceuticals, Inc. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
| Cook Medical LLC | 1 | $14 |
| Penumbra, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Alto Abdominal Stent Graft System$20,326
- AFX$11,804
- AFX2 Bifurcated Endograft System$9,300
- Ovation$8,100
- Peripheral Orbital Atherectomy System$1,950
- GORE CARDIOFORM Septal Occluder$1,283
- Ovation iX Iliac Stent Graft$600
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$125
- PuraPly$118
- COSEAL$117
- MetaCross$113
- CARDIOMEMS$111
How this compares
$51,969 in reported general payments places this provider in the 90th percentile of 109 interventional cardiology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 462 | $356,462 |
| Repatha SureclickEvolocumab | 135 | $74,602 |
| XareltoRivaroxaban | 58 | $59,130 |
| JardianceEmpagliflozin | 46 | $49,484 |
| EntrestoSacubitril/Valsartan | 46 | $43,401 |
| Praluent PenAlirocumab | 45 | $22,454 |
| Atorvastatin Calcium | 527 | $7,878 |
| Metoprolol Succinate | 301 | $5,204 |
| Ranolazine ErRanolazine | 48 | $4,369 |
| Losartan Potassium | 227 | $3,649 |
| Ezetimibe | 134 | $3,640 |
| Carvedilol | 332 | $3,031 |
| Varenicline Tartrate | 13 | $2,853 |
| Chlorthalidone | 110 | $2,810 |
| Rosuvastatin Calcium | 100 | $2,485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $221 | $356,462462 claims |
| Johnson & JohnsonXarelto | $115 | $59,13058 claims |
| Boehringer IngelheimJardiance | $148 | $49,48446 claims |
| NovartisEntresto | $600 | $43,40146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 109 interventional cardiology providers in Alabama.
Other interventional cardiology in Birmingham
- Gary RoubinBirmingham$157K
- Robert FosterBirmingham$90K
- Hasan GuvenBirmingham$86K
- Abdullah MahmoodBirmingham$61K
- Ali EbrahimiBirmingham$55K
- Kamran AliBirmingham$47K
- Mouhamed SabouniBirmingham$44K
- David SchultzBirmingham$19K
- Tushar MishraBirmingham$17K
- Arka ChatterjeeBirmingham$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.